A major genetic accelerator of cancer diagnosis: rs867228 in FPR1

Zsofia Sztupinszki; Julie Le Naour; Erika Vacchelli; Pierre Laurent-Puig; Suzette Delaloge; Zoltan Szallasi; Guido Kroemer

doi:10.1080/2162402X.2020.1859064

A major genetic accelerator of cancer diagnosis: rs867228 in FPR1

Zsofia Sztupinszki, Julie Le Naour, Erika Vacchelli, Pierre Laurent-Puig, Suzette Delaloge, Zoltan Szallasi, Guido Kroemer

Research output: Contribution to journal › Editorial

6 Citations (Scopus)

Original language	English
Article number	1859064
Journal	OncoImmunology
Volume	10
Issue number	1
DOIs	https://doi.org/10.1080/2162402X.2020.1859064
Publication status	Published - 1 Jan 2021

Access to Document

10.1080/2162402X.2020.1859064

Cite this

@article{f8e7005a274142fc8fb690b9aec19104,

title = "A major genetic accelerator of cancer diagnosis: rs867228 in FPR1",

author = "Zsofia Sztupinszki and \{Le Naour\}, Julie and Erika Vacchelli and Pierre Laurent-Puig and Suzette Delaloge and Zoltan Szallasi and Guido Kroemer",

note = "Funding Information: Z.S. is supported by the Research and Technology Innovation Fund (KTIA\_NAP\_13-2014-0021 and NAP2-2017-1.2.1-NKP-0002 to Z.S.); Breast Cancer Research Foundation (BCRF-18-159 to Z.S.) and the Novo Nordisk Foundation Interdisciplinary Synergy Programme Grant (NNF15OC0016584), Det Fri Forskningsrad (award number 19\#7016-00345B); Department of Defense through the Prostate Cancer Research Program (award number is W81XWH-18-2-0056). The results shown here are partly based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov. Funding Information: GK is supported by the Ligue contre le Cancer ({\'e}quipe labellis{\'e}e); Agence National de la Recherche (ANR) – Projets blancs; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Association “Ruban Rose”; Canc{\'e}rop{\^o}le Ile-de-France; Chancelerie des universit{\'e}s de Paris (Legs Poix), Fondation pour la Recherche M{\'e}dicale (FRM); a donation by Elior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy Odyssea, the European Union Horizon 2020 Project Oncobiome; Fondation Carrefour; High-end Foreign Expert Program in China (GDW20171100085), Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology (ANR-18-IDEX-0001); the RHU Torino Lumi{\`e}re; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM).",

year = "2021",

month = jan,

day = "1",

doi = "10.1080/2162402X.2020.1859064",

language = "English",

volume = "10",

journal = "OncoImmunology",

issn = "2162-4011",

number = "1",

}

TY - JOUR

T1 - A major genetic accelerator of cancer diagnosis

T2 - rs867228 in FPR1

AU - Sztupinszki, Zsofia

AU - Le Naour, Julie

AU - Vacchelli, Erika

AU - Laurent-Puig, Pierre

AU - Delaloge, Suzette

AU - Szallasi, Zoltan

AU - Kroemer, Guido

N1 - Funding Information: Z.S. is supported by the Research and Technology Innovation Fund (KTIA_NAP_13-2014-0021 and NAP2-2017-1.2.1-NKP-0002 to Z.S.); Breast Cancer Research Foundation (BCRF-18-159 to Z.S.) and the Novo Nordisk Foundation Interdisciplinary Synergy Programme Grant (NNF15OC0016584), Det Fri Forskningsrad (award number 19#7016-00345B); Department of Defense through the Prostate Cancer Research Program (award number is W81XWH-18-2-0056). The results shown here are partly based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov. Funding Information: GK is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR) – Projets blancs; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Association “Ruban Rose”; Cancéropôle Ile-de-France; Chancelerie des universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM); a donation by Elior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy Odyssea, the European Union Horizon 2020 Project Oncobiome; Fondation Carrefour; High-end Foreign Expert Program in China (GDW20171100085), Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology (ANR-18-IDEX-0001); the RHU Torino Lumière; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM).

PY - 2021/1/1

Y1 - 2021/1/1

UR - http://www.scopus.com/inward/record.url?scp=85099097776&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2020.1859064

DO - 10.1080/2162402X.2020.1859064

M3 - Editorial

C2 - 33489470

AN - SCOPUS:85099097776

SN - 2162-4011

VL - 10

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - 1859064

ER -

A major genetic accelerator of cancer diagnosis: rs867228 in FPR1

Access to Document

Other files and links

Cite this